Cytological Immunostaining of HMGA2, LRP1B, and TP63 as Potential Biomarkers for Triaging Human Papillomavirus-Positive Women

Background: Since human papillomavirus (HPV) DNA testing has been promoted as primary screening strategy, the triage method has also evolved from morphological testing to a molecular biomarker detection to improve screening efficiency. In this study, we investigated the performance of three HPV integration hot-spots, HMGA2, LRP1B, and TP63, as potential triage markers in HPV screening tests. Materials and Methods: This cross-sectional study was conducted from November 2016 to December 2017 in the First Affiliated Hospital of Sun Yat-sen University. Immunocytochemistry was carried out using residual cervical cell samples from 121 HPV-positive cases (23 normal, 24 cervical intraepithelial neoplasia (CIN) 1, and 74 CIN2+). Results: Of the 121 cases, 77 showed completely paired for the three biomarkers. In these 77 cases, receiver operating characteristic (ROC) analysis of HMGA2 showed the best potential for detecting CIN2+ among HPV+ cases (sensitivity 70%; specificity 91.89%; AUC 0.839). TP63 was second most effective biomarker (AUC 0.838; sensitivity 80%; specificity 81.08%). In contrast, LRP1B had the smallest AUC (0.801) among the three biomarkers but had the highest sensitivity (90%) and specificity (56.76%). To test the triage value of combining the three biomarkers, logistic regression was conducted followed by ROC comparison analysis. Promisingly, the combination of the three biomarkers gave the largest AUC of 0.951 with 92.5% sensitivity and 89.1% specificity (P < .0001 compared to liquid-based cytology test by Z-test). Conclusions: A combination of HMGA2, LRP1B, and TP63 as potential biomarkers may be useful for screening during triage of HPV-positive patients, particularly for detecting CIN2 + .

[1]  J. Herz,et al.  Expression of a recombinant full-length LRP1B receptor in human non-small cell lung cancer cells confirms the postulated growth-suppressing function of this large LDL receptor family member , 2016, Oncotarget.

[2]  B. Feng,et al.  Increased high mobility group A 2 expression promotes transition of cervical intraepithelial neoplasm into cervical cancer , 2018, Oncotarget.

[3]  X. Fang,et al.  Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism , 2015, Nature Genetics.

[4]  H. Kuramoto,et al.  Performance of p16INK4a/Ki-67 immunocytochemistry for identifying CIN2+ in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion specimens: a Japanese Gynecologic Oncology Group study , 2014, International Journal of Clinical Oncology.

[5]  Jian-Jun Wei,et al.  HMGA2 and high-grade serous ovarian carcinoma , 2013, Journal of Molecular Medicine.

[6]  Lars Jansen,et al.  Non-Random Integration of the HPV Genome in Cervical Cancer , 2012, PloS one.

[7]  Y. Okada,et al.  HMGA2 is a driver of tumor metastasis. , 2013, Cancer research.

[8]  Cara M Martin,et al.  The Value of a Novel Panel of Cervical Cancer Biomarkers for Triage of HPV Positive Patients and for Detecting Disease Progression , 2017, Pathology & Oncology Research.

[9]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[10]  Ying Liang,et al.  Low-molecular-mass secretome profiling identifies HMGA2 and MIF as prognostic biomarkers for oral cavity squamous cell carcinoma , 2015, Scientific Reports.

[11]  R. Holm,et al.  The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma—differences in histological subtypes , 2016, BMC Cancer.

[12]  Yan Lu,et al.  Targeted, Deep Sequencing Reveals Full Methylation Profiles of Multiple HPV Types and Potential Biomarkers for Cervical Cancer Progression , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[13]  Ranjit Thorat,et al.  HPV screening for cervical cancer in rural India. , 2009, The New England journal of medicine.

[14]  E. J. Mayeaux,et al.  Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. , 2015, Gynecologic oncology.

[15]  Kui Wu,et al.  Integrative analysis of genomic sequencing data reveals higher prevalence of LRP1B mutations in lung adenocarcinoma patients with COPD , 2017, Scientific Reports.

[16]  S. Yaklichkin,et al.  Genomic organization of a new candidate tumor suppressor gene, LRP1B. , 2000, Genomics.

[17]  A. Jauch,et al.  Alteration of the LRP1B Gene Region Is Associated with High Grade of Urothelial Cancer , 2002, Laboratory Investigation.

[18]  Pierre Laurent-Puig,et al.  DeltaN TP63 reactivation, epithelial phenotype maintenance, and survival in lung squamous cell carcinoma , 2012, Tumor Biology.

[19]  Yang Ke,et al.  Comprehensive mapping of the human papillomavirus (HPV) DNA integration sites in cervical carcinomas by HPV capture technology , 2015, Oncotarget.

[20]  Ziwei Wang,et al.  Coexpression of HMGA2 and Oct4 predicts an unfavorable prognosis in human gastric cancer , 2014, Medical Oncology.

[21]  T. Carey,et al.  Genomic Integration of High-Risk HPV Alters Gene Expression in Oropharyngeal Squamous Cell Carcinoma , 2016, Molecular Cancer Research.

[22]  S. Wilting,et al.  Molecular events leading to HPV-induced high grade neoplasia , 2016, Papillomavirus research.

[23]  Jun Li,et al.  Down‐regulation of LRP1B in colon cancer promoted the growth and migration of cancer cells , 2017, Experimental cell research.

[24]  G. Melino,et al.  TAp63α induces apoptosis by activating signaling via death receptors and mitochondria , 2005, The EMBO journal.

[25]  Y. Li,et al.  MicroRNA Detection in Cervical Exfoliated Cells as a Triage for Human Papillomavirus–Positive Women , 2014, Journal of the National Cancer Institute.

[26]  B. Vojtesek,et al.  The role of P63 in cancer, stem cells and cancer stem cells , 2011, Cellular & Molecular Biology Letters.

[27]  M. Sobrinho-Simões,et al.  Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells , 2011, Oncogene.

[28]  George E. Allen,et al.  Human embryonic lung epithelial tips are multipotent progenitors that can be expanded in vitro as long-term self-renewing organoids , 2017, eLife.

[29]  C. Cordon-Cardo,et al.  ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer. , 2015, Journal of Urology.

[30]  Isabelle Cleynen,et al.  The HMGA proteins: a myriad of functions (Review). , 2008, International journal of oncology.

[31]  H. Cubie,et al.  Increased Cycling Cell Numbers and Stem Cell Associated Proteins as Potential Biomarkers for High Grade Human Papillomavirus+ve Pre-Neoplastic Cervical Disease , 2014, PloS one.

[32]  M. Schiffman,et al.  p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women. , 2015, Journal of the National Cancer Institute.

[33]  A. Longatto-Filho,et al.  HPV DNA testing with cytology triage in cervical cancer screening: Influence of revealing HPV infection status , 2015, Cancer cytopathology.

[34]  T. Wright,et al.  Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. , 2015, Gynecologic oncology.

[35]  E. Franco,et al.  Comparison of Triage Strategies for HPV-Positive Women: Canadian Cervical Cancer Screening Trial Results , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[36]  E. J. Mayeaux,et al.  Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical Guidance , 2015, Obstetrics and gynecology.

[37]  M. Ohira,et al.  Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis. , 2017, Gynecologic oncology.